GSK plc (LON:GSK) Insider Emma Walmsley Sells 5,473 Shares

GSK plc (LON:GSK) insider Emma Walmsley sold 5,473 shares of the stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.20), for a total value of £79,303.77 ($105,065.94).

Emma Walmsley also recently made the following trade(s):

• On Monday, February 17th, Emma Walmsley sold 38,459 shares of GSK stock. The stock was sold at an average price of GBX 1,418 ($18.79), for a total value of £545,348.62 ($722,507.45).
• On Monday, February 10th, Emma Walmsley sold 120,653 shares of GSK stock. The shares were sold at an average price of GBX 1,453 ($19.25), for a total value of £1,753,088.09 ($2,322,586.23).

GSK Stock Down 1.1 %

Shares of GSK opened at GBX 1,364 ($18.07) on Friday. The stock has a fifty day simple moving average of GBX 1,427.63 and a two-hundred day simple moving average of GBX 1,398.27. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The company has a market capitalization of £55.35 billion, a PE ratio of 22.03, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK plc has a 52-week low of GBX 1,242.50 ($16.46) and a 52-week high of GBX 1,823.50 ($24.16).

GSK (LON:GSK) last issued its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.59) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities analysts forecast that GSK plc will post 175.980975 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on GSK shares. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Friday, March 28th. Shore Capital restated a “buy” rating on shares of GSK in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,862.50 ($24.68).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.